🔬ResearchInvestigational Quadruple Receptor Agonist Shows Weight Loss Potential in Phase II Trial
A phase II clinical trial suggests the oral medication NA-931 may facilitate significant weight loss while potentially preserving lean muscle mass. The drug targets four …